As of June 18, 2025, Evofem Biosciences Inc (EVFM) reports a Net Margin of -45.76%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Evofem Biosciences Inc's Net Margin
Over recent years, Evofem Biosciences Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -45.76% |
| 2023-12-31 | 290.81% |
| 2022-12-31 | -455.53% |
| 2021-12-31 | -2488.99% |
| 2020-12-31 | -31907.85% |
This steady improvement highlights how Evofem Biosciences Inc manages its overall profitability and cost control over time.
Comparing Evofem Biosciences Inc's Net Margin to Peers
To better understand Evofem Biosciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Evofem Biosciences Inc (EVFM) | -45.76% |
| AcelRx Pharmaceuticals Inc (ACRX) | 2698.31% |
| SOL Global Investments Corp (SOL.CN) | 133.62% |
| Royalty Pharma PLC (RPRX) | 37.95% |
| Next Green Wave Holdings Inc (NGW.CN) | 27.40% |
| Zoetis Inc (ZTS) | 26.86% |
Compared to its competitors, Evofem Biosciences Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.